• Provision of signed and dated informed consent form;

• Aged 18 to 75 years old;

• Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma;

• Completed an R0 or R1 surgical resection as determined by pathology；

• Have not received any prior neoadjuvant therapy;

• ECOG score is 0 or 1;

• Life expectancy of greater than 12 months;

• CA19-9 \<100U/mL before initial chemotherapy;

• Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.

• Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.